Toma Biosciences

cancer testing technology


Every cancer patient’s tumor has unique genomic errors. Recent efforts by the National Cancer Institute (NCI) and the National Institute of Health (NIH) have revealed how important these genomic differences are in treating cancer.

TOMA’s mission is to provide physicians with accurate information about the errors present in a patient’s tumor.

Until now, physicians and their patients have relied on an anatomical approach to diagnose and treat cancer. Now TOMA offers the AmplinomeTM Test, a digitial molecular test that identifies genomic errors in a patient’s tumor and provides information that can help guide treatment and enable physicians to uncover new treatment options. TOMA is the first company to offer a test of this kind.

  • Location: Foster City, CA
  • Paladin Initial Investment Date: January 2014

Portfolio Stats

Over 65 Companies

Paladin has invested in over 65 portfolio companies since 2001.

4 Continents

Paladin has invested in companies in North America, Australia, Europe, and South America.

Over $1 billion

Paladin manages over $1 billion of committed capital across multiple funds and investment vehicles.